Rating Change
Jones Trading reiterated its Buy rating on Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI) on August 14, 2026.
reiterateNASDAQ:TRVI
Jones Trading Reiterates Buy Rating on Trevi Therapeutics, Inc. Common Stock (TRVI)
Jones Trading reiterated its Buy rating on Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI) on August 14, 2026.
At publication ·
What changed
Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI) · reiterate
- Firm
- Jones Trading
- Rating
- Buy to Buy
- Price at event
- $18.49
- Market capitalization
- $1.7B
At a glance
Key takeaways
- Jones Trading reiterated a Buy rating on Trevi Therapeutics (TRVI) on August 14, 2026, with the stock trading at $18.49 and a market capitalization of $1.7 billion.
- Among the 10 most recent analyst ratings, all 10 are Buy ratings with zero Hold or Sell ratings, indicating unanimous bullish sentiment from recent analyst coverage.
Market Context
Trevi Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $18.49 with a market capitalization of $1.7B.
Analyst coverage from Jones Trading provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Trevi Therapeutics, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Trevi Therapeutics, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Jones Trading | Buy | N/A |
| Aug 07, 2026 | Oppenheimer | Outperform | N/A |
| Aug 07, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jul 21, 2026 | BMO Capital | Outperform | N/A |
| Jul 20, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TRVI Stock Page
Frequently Asked Questions
What does the Buy rating mean for TRVI?
A rating of Buy from Jones Trading reflects the analyst's outlook on Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TRVI forecast page.